ClinicalTrials.gg
CompletedNCT02969018Updated Mar 29, 2019Results posted

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

A Phase 2 interventional study of PF-06700841 and Placebo in Chronic Plaque Psoriasis, sponsored by Pfizer. Completed at 44 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.

Enrollment
15th of 42
212 · median 120
Started
2016
the only one that year
Phase 2
13 of 57
none open now
Registered
50th of 57
by date

Among the 57 studies in Psoriasis by Pfizer, this one is the 15th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2016, is one of 13 in phase 2, and was the 50th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Psoriasis by Pfizer as a file.
02

Study summary

The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • plaque psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug)
  • Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline/Day 1 (prior to first dose of study drug)
  • Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug)
  • Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)

Exclusion criteria

Exclusion Criteria:

  • Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed
  • Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis
  • Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA)
  • Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).
  • Have taken Apremilast (Otezla) within 3 months of first dose of study drug.
  • Have undergone treatment with tofacitinib within 3 months of first dose.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    PF-06700841 60 mg followed by 30 mg once daily

    4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily

    Drug: PF-06700841

  • Experimental
    PF-06700841 60 mg followed by 10 mg once daily

    4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily

    Drug: PF-06700841

  • Experimental
    PF-06700841 60mg once daily followed by 100mg once weekly

    4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly

    Drug: PF-06700841

  • Experimental
    PF-06700841 60mg once daily followed by placebo once daily

    4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily

    Drug: PF-06700841

  • Experimental
    PF-06700841 30mg once daily

    4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily

    Drug: PF-06700841

  • Experimental
    PF-06700841 30mg once daily followed by 10mg once daily

    4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily

    Drug: PF-06700841

  • Experimental
    PF-06700841 30mg once daily followed by 100mg once weekly

    4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly

    Drug: PF-06700841

  • Placebo comparator
    Placebo

    12 weeks once daily placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Baseline (Day 1 pre-dose), Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

    A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Week 12

  2. Change From Baseline in PASI Scores at Week 4 by Induction Dose

    Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Baseline (Day 1 pre-dose), Week 4

  3. Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16

    A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Weeks 1, 2, 4, 6, 8, 10, 14, 16

  4. Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

    A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

  5. Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

    A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

  6. Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16

    The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16

  7. Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

    The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

    Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

  8. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

    Time frame: From first dose of study treatment (Day 1) up to Week 20

  9. Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs

    The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).

    Time frame: From first dose of study treatment (Day 1) up to Week 20

  10. Change From Baseline in Blood Lipid Level at Weeks 4 and 12

    Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.

    Time frame: Baseline (Day 1 pre-dose), Weeks 4 and 12

  11. Number of Participants With Any Post-Baseline Laboratory Test Abnormalities

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).

    Time frame: From first dose of study treatment (Day 1) up to Week 16

  12. Number of Participants With Post-Baseline Vital Sign Abnormalities

    Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.

    Time frame: From first dose of study treatment (Day 1) up to Week 16

  13. Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

    ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.

    Time frame: From first dose of study treatment (Day 1) up to Week 16

07

Results

Posted Mar 29, 2019

Participant flow

Participant flow — Overall Study
MilestonePF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Started2529262529253023
Completed2121202027172216
Not completed48652887
Withdrew: Adverse event24120120
Withdrew: Lack of efficacy01001111
Withdrew: Lost to follow-up12201101
Withdrew: No longer meets eligibility criteria00000010
Withdrew: Non-compliance with study drug10000000
Withdrew: Other00010002
Withdrew: Pregnancy00000100
Withdrew: Protocol violation00110000
Withdrew: Withdrawal by subject01210443

Outcome measures

PrimaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Baseline (Day 1 pre-dose), Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
units on a scalePF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12-15.85 (-18.31 to -13.39)-10.56 (-12.96 to -8.16)-14.28 (-16.75 to -11.81)-10.14 (-12.62 to -7.66)-17.28 (-19.55 to -15.02)-13.27 (-15.78 to -10.76)-11.88 (-14.16 to -9.59)-7.21 (-9.96 to -4.46)
Statistical analysis
  • PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD vs Placebo · Mixed Models Analysis · p = 0.0005 (Hochberg adjusted p-value) · Least squares mean difference: -8.64 · 90% CI -12.33 to -4.95
  • PF-06700841 60 mg QD Followed by 10 mg QD vs Placebo · Mixed Models Analysis · p = 0.0963 (Hochberg adjusted p-value) · Least squares mean difference: -3.34 · 90% CI -6.99 to 0.30
  • PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) vs Placebo · Mixed Models Analysis · p = 0.0046 (Hochberg adjusted p-value) · Least squares mean difference: -7.07 · 90% CI -10.76 to -3.37
  • PF-06700841 60 mg QD Followed by Placebo vs Placebo · Mixed Models Analysis · p = 0.0963 (Hochberg adjusted p-value) · Least squares mean difference: -2.93 · 90% CI -6.63 to 0.77
  • PF-06700841 30 mg QD vs Placebo · Mixed Models Analysis · p = <0.0001 (Hochberg adjusted p-value) · Least squares mean difference: -10.07 · 90% CI -13.63 to -6.51
  • PF-06700841 30 mg QD Followed by 10 mg QD vs Placebo · Mixed Models Analysis · p = 0.0158 (Hochberg adjusted p-value) · Least squares mean difference: -6.06 · 90% CI -9.79 to -2.33
  • PF-06700841 30 mg QD Followed by 100 mg QW vs Placebo · Mixed Models Analysis · p = 0.0488 (Hochberg adjusted p-value) · Least squares mean difference: -4.66 · 90% CI -8.24 to -1.09
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
percentage of participantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 1260.0 (41.68 to 76.44)24.1 (11.92 to 40.60)57.7 (39.84 to 74.16)24.0 (11.01 to 41.95)86.2 (71.16 to 95.15)24.0 (11.01 to 41.95)36.7 (22.11 to 53.31)13.0 (3.65 to 30.36)
Statistical analysis
  • PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD vs Placebo · Odds ratio (or): 10.00 · 90% CI 2.95 to 33.87
  • PF-06700841 60 mg QD Followed by 10 mg QD vs Placebo · Odds ratio (or): 2.12 · 90% CI 0.61 to 7.36
  • PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) vs Placebo · Odds ratio (or): 9.09 · 90% CI 2.71 to 30.48
  • PF-06700841 60 mg QD Followed by Placebo vs Placebo · Odds ratio (or): 2.11 · 90% CI 0.59 to 7.55
  • PF-06700841 30 mg QD vs Placebo · Odds ratio (or): 41.67 · 90% CI 10.80 to 160.68
  • PF-06700841 30 mg QD Followed by 10 mg QD vs Placebo · Odds ratio (or): 2.11 · 90% CI 0.59 to 7.55
  • PF-06700841 30 mg QD Followed by 100 mg QW vs Placebo · Odds ratio (or): 3.86 · 90% CI 1.17 to 12.74
SecondaryChange From Baseline in PASI Scores at Week 4 by Induction Dose

Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Baseline (Day 1 pre-dose), Week 4
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI Scores at Week 4 by Induction Dose
units on a scalePF-06700841 60 mg QD as the Induction DosePF-06700841 30 mg QD as the Induction DosePlacebo as the Induction Dose
Change From Baseline in PASI Scores at Week 4 by Induction Dose-13.17 (-14.20 to -12.15)-12.16 (-13.31 to -11.02)-4.17 (-6.38 to -1.97)
Statistical analysis
  • PF-06700841 60 mg QD as the Induction Dose vs Placebo as the Induction Dose · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: -9.00 · 90% CI -11.43 to -6.57
  • PF-06700841 30 mg QD as the Induction Dose vs Placebo as the Induction Dose · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: -7.99 · 90% CI -10.48 to -5.51
SecondaryPercentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16

A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Weeks 1, 2, 4, 6, 8, 10, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16
percentage of participantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Week 10 (0.00 to 11.29)6.9 (1.24 to 20.16)7.7 (1.38 to 22.29)4.0 (0.20 to 17.61)0 (0.00 to 9.81)4.0 (0.20 to 17.61)0 (0.00 to 9.50)0 (0.00 to 12.21)
Week 28.0 (1.44 to 23.10)13.8 (4.85 to 28.84)26.9 (13.38 to 44.68)12.0 (3.35 to 28.17)3.4 (0.18 to 15.34)8.0 (1.44 to 23.10)0 (0.00 to 9.50)0 (0.00 to 12.21)
Week 424.0 (11.01 to 41.95)41.4 (25.89 to 58.25)61.5 (43.57 to 77.43)36.0 (20.24 to 54.39)27.6 (14.53 to 44.29)24.0 (11.01 to 41.95)36.7 (22.11 to 53.31)0 (0.00 to 12.21)
Week 644.0 (26.99 to 62.14)41.4 (25.89 to 58.25)65.4 (47.38 to 80.60)36.0 (20.24 to 54.39)51.7 (35.20 to 67.97)28.0 (13.95 to 46.22)26.7 (14.02 to 42.99)8.7 (1.57 to 24.92)
Week 860.0 (41.68 to 76.44)37.9 (22.93 to 54.88)65.4 (47.38 to 80.60)32.0 (17.03 to 50.36)65.5 (48.57 to 79.95)20.0 (8.23 to 37.54)40.0 (24.95 to 56.61)8.7 (1.57 to 24.92)
Week 1048.0 (30.51 to 65.86)24.1 (11.92 to 40.60)61.5 (43.57 to 77.43)32.0 (17.03 to 50.36)72.4 (55.71 to 85.47)28.0 (13.95 to 46.22)46.7 (30.85 to 63.01)13.0 (3.65 to 30.36)
Week 1448.0 (30.51 to 65.86)17.2 (7.05 to 32.89)34.6 (19.40 to 52.62)16.0 (5.66 to 32.96)75.9 (59.40 to 88.08)16.0 (5.66 to 32.96)16.7 (6.81 to 31.90)8.7 (1.57 to 24.92)
Week 1636.0 (20.24 to 54.39)10.3 (2.88 to 24.61)30.8 (16.33 to 48.70)20.0 (8.23 to 37.54)58.6 (41.75 to 74.11)12.0 (3.35 to 28.17)16.7 (6.81 to 31.90)8.7 (1.57 to 24.92)
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
percentage of participantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Week 112.0 (3.35 to 28.17)13.8 (4.85 to 28.84)19.2 (7.90 to 36.26)20.0 (8.23 to 37.54)10.3 (2.88 to 24.61)8.0 (1.44 to 23.10)3.3 (0.17 to 14.86)0 (0.00 to 12.21)
Week 244.0 (26.99 to 62.14)37.9 (22.93 to 54.88)46.2 (29.21 to 63.79)32.0 (17.03 to 50.36)41.4 (25.89 to 58.25)20.0 (8.23 to 37.54)33.3 (19.33 to 49.94)0 (0.00 to 12.21)
Week 460.0 (41.68 to 76.44)69.0 (52.10 to 82.75)69.2 (51.30 to 83.67)68.0 (49.64 to 82.97)69.0 (52.10 to 82.75)60.0 (41.68 to 76.44)66.7 (50.06 to 80.67)13.0 (3.65 to 30.36)
Week 672.0 (53.78 to 86.05)62.1 (45.12 to 77.07)73.1 (55.32 to 86.62)68.0 (49.64 to 82.97)82.8 (67.11 to 92.95)60.0 (41.68 to 76.44)63.3 (46.69 to 77.89)26.1 (12.02 to 45.10)
Week 872.0 (53.78 to 86.05)55.2 (38.44 to 71.07)73.1 (55.32 to 86.62)52.0 (34.14 to 69.49)86.2 (71.16 to 95.15)56.0 (37.86 to 73.01)63.3 (46.69 to 77.89)17.4 (6.17 to 35.49)
Week 1068.0 (49.64 to 82.97)44.8 (28.93 to 61.56)73.1 (55.32 to 86.62)48.0 (30.51 to 65.86)86.2 (71.16 to 95.15)48.0 (30.51 to 65.86)56.7 (40.16 to 72.13)17.4 (6.17 to 35.49)
Week 1268.0 (49.64 to 82.97)44.8 (28.93 to 61.56)69.2 (51.30 to 83.67)52.0 (34.14 to 69.49)89.7 (75.39 to 97.12)48.0 (30.51 to 65.86)53.3 (36.99 to 69.15)21.7 (8.98 to 40.39)
Week 1464.0 (45.61 to 79.76)44.8 (28.93 to 61.56)61.5 (43.57 to 77.43)48.0 (30.51 to 65.86)89.7 (75.39 to 97.12)36.0 (20.24 to 54.39)36.7 (22.11 to 53.31)26.1 (12.02 to 45.10)
Week 1660.0 (41.68 to 76.44)34.5 (20.05 to 51.43)53.8 (36.21 to 70.79)40.0 (23.56 to 58.32)79.3 (63.20 to 90.58)40.0 (23.56 to 58.32)36.7 (22.11 to 53.31)21.7 (8.98 to 40.39)
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
percentage of participantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Week 10 (0.00 to 11.29)3.4 (0.18 to 15.34)0 (0.00 to 10.88)0 (0.00 to 11.29)0 (0.00 to 9.81)0 (0.00 to 11.29)0 (0.00 to 9.50)0 (0.00 to 12.21)
Week 20 (0.00 to 11.29)3.4 (0.18 to 15.34)7.7 (1.38 to 22.29)0 (0.00 to 11.29)0 (0.00 to 9.81)0 (0.00 to 11.29)0 (0.00 to 9.50)0 (0.00 to 12.21)
Week 412.0 (3.35 to 28.17)20.7 (9.42 to 36.80)42.3 (25.84 to 60.16)16.0 (5.66 to 32.96)6.9 (1.24 to 20.16)8.0 (1.44 to 23.10)3.3 (0.17 to 14.86)0 (0.00 to 12.21)
Week 616.0 (5.66 to 32.96)20.7 (9.42 to 36.80)26.9 (13.38 to 44.68)12.0 (3.35 to 28.17)24.1 (11.92 to 40.60)8.0 (1.44 to 23.10)20.0 (9.09 to 35.70)0 (0.00 to 12.21)
Week 824.0 (11.01 to 41.95)17.2 (7.05 to 32.89)30.8 (16.33 to 48.70)8.0 (1.44 to 23.10)34.5 (20.05 to 51.43)4.0 (0.20 to 17.61)16.7 (6.81 to 31.90)0 (0.00 to 12.21)
Week 1028.0 (13.95 to 46.22)17.2 (7.05 to 32.89)26.9 (13.38 to 44.68)8.0 (1.44 to 23.10)34.5 (20.05 to 51.43)8.0 (1.44 to 23.10)13.3 (4.69 to 27.96)4.3 (0.22 to 19.02)
Week 1236.0 (20.24 to 54.39)13.8 (4.85 to 28.84)26.9 (13.38 to 44.68)8.0 (1.44 to 23.10)51.7 (35.20 to 67.97)8.0 (1.44 to 23.10)10.0 (2.78 to 23.86)4.3 (0.22 to 19.02)
Week 1428.0 (13.95 to 46.22)13.8 (4.85 to 28.84)11.5 (3.22 to 27.19)8.0 (1.44 to 23.10)37.9 (22.93 to 54.88)4.0 (0.20 to 17.61)13.3 (4.69 to 27.96)4.3 (0.22 to 19.02)
Week 1620.0 (8.23 to 37.54)3.4 (0.18 to 15.34)15.4 (5.43 to 31.82)4.0 (0.20 to 17.61)27.6 (14.53 to 44.29)8.0 (1.44 to 23.10)10.0 (2.78 to 23.86)4.3 (0.22 to 19.02)
SecondaryChange From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16

The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16
Reported as:
Mean · units on a scale
Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16
units on a scalePF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Week 1-5.74 (-7.61 to -3.86)-4.60 (-6.06 to -3.14)-5.85 (-7.62 to -4.08)-5.37 (-7.59 to -3.15)-3.97 (-5.00 to -2.95)-4.41 (-6.18 to -2.64)-3.46 (-4.64 to -2.28)-1.35 (-2.03 to -0.66)
Week 2-9.44 (-11.74 to -7.15)-8.35 (-10.07 to -6.63)-10.79 (-13.05 to -8.52)-9.49 (-12.40 to -6.58)-7.86 (-9.38 to -6.35)-7.79 (-9.79 to -5.79)-7.93 (-9.64 to -6.22)-2.28 (-3.21 to -1.36)
Week 4-12.85 (-15.76 to -9.94)-12.19 (-14.57 to -9.81)-14.11 (-16.37 to -11.86)-13.91 (-16.98 to -10.85)-11.72 (-13.61 to -9.83)-12.88 (-15.49 to -10.27)-13.06 (-15.58 to -10.53)-4.02 (-6.04 to -2.00)
Week 6-15.00 (-18.30 to -11.71)-12.12 (-14.53 to -9.71)-15.00 (-17.35 to -12.66)-13.85 (-16.62 to -11.08)-14.30 (-16.24 to -12.36)-14.33 (-17.47 to -11.19)-14.17 (-16.92 to -11.41)-5.52 (-7.58 to -3.45)
Week 8-15.94 (-19.40 to -12.49)-11.09 (-12.90 to -9.27)-14.97 (-17.66 to -12.27)-12.87 (-15.69 to -10.04)-15.82 (-17.81 to -13.84)-14.27 (-17.51 to -11.03)-13.83 (-16.79 to -10.87)-6.56 (-8.61 to -4.51)
Week 10-16.54 (-20.54 to -12.54)-9.89 (-12.16 to -7.61)-15.52 (-18.09 to -12.96)-11.64 (-14.92 to -8.37)-16.65 (-18.64 to -14.66)-14.98 (-18.43 to -11.53)-12.97 (-16.19 to -9.74)-6.78 (-9.20 to -4.37)
Week 14-15.47 (-19.88 to -11.06)-8.11 (-10.69 to -5.53)-13.31 (-16.73 to -9.89)-9.45 (-12.96 to -5.94)-16.14 (-18.16 to -14.12)-10.44 (-13.33 to -7.55)-11.03 (-14.61 to -7.44)-6.98 (-9.81 to -4.14)
Week 16-14.16 (-18.68 to -9.64)-6.59 (-9.09 to -4.09)-13.00 (-16.60 to -9.40)-7.83 (-11.56 to -4.11)-14.38 (-16.74 to -12.01)-9.62 (-13.08 to -6.16)-9.13 (-13.94 to -4.33)-6.76 (-9.80 to -3.72)
SecondaryPercent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame:
Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Reported as:
Mean · percent change
Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
percent changePF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Week 1-26.70 (-33.80 to -19.60)-24.66 (-33.24 to -16.08)-30.25 (-39.07 to -21.44)-23.33 (-30.84 to -15.82)-20.92 (-26.82 to -15.01)-17.50 (-23.91 to -11.10)-15.42 (-20.68 to -10.16)-6.90 (-10.50 to -3.30)
Week 2-43.66 (-52.81 to -34.52)-44.17 (-52.75 to -35.59)-54.27 (-64.17 to -44.36)-42.58 (-51.17 to -33.98)-40.89 (-47.94 to -33.83)-32.46 (-39.75 to -25.16)-35.89 (-42.69 to -29.09)-12.81 (-18.29 to -7.33)
Week 4-57.16 (-67.35 to -46.97)-63.02 (-72.12 to -53.91)-72.41 (-82.31 to -62.51)-64.71 (-72.81 to -56.61)-60.76 (-68.38 to -53.14)-53.93 (-62.59 to -45.28)-58.99 (-67.94 to -50.03)-25.17 (-34.24 to -16.09)
Week 6-66.07 (-76.06 to -56.08)-63.31 (-73.99 to -52.62)-75.96 (-84.68 to -67.25)-65.06 (-74.15 to -55.97)-73.91 (-80.62 to -67.19)-58.57 (-66.76 to -50.37)-63.17 (-72.37 to -53.96)-33.49 (-44.16 to -22.83)
Week 8-70.11 (-80.95 to -59.27)-62.25 (-72.42 to -52.07)-77.05 (-86.69 to -67.41)-59.88 (-69.78 to -49.97)-81.04 (-86.69 to -75.40)-58.32 (-66.39 to -50.25)-61.38 (-71.80 to -50.96)-37.76 (-47.73 to -27.80)
Week 10-70.72 (-83.32 to -58.12)-57.55 (-69.11 to -46.00)-78.46 (-85.82 to -71.09)-53.81 (-64.41 to -43.22)-84.82 (-89.50 to -80.15)-61.23 (-69.29 to -53.17)-57.24 (-68.80 to -45.69)-39.68 (-50.92 to -28.44)
Week 12-71.94 (-84.67 to -59.21)-58.52 (-69.38 to -47.67)-74.42 (-84.98 to -63.87)-51.49 (-63.21 to -39.78)-88.68 (-93.13 to -84.22)-57.81 (-68.52 to -47.10)-58.57 (-70.05 to -47.09)-40.27 (-52.68 to -27.86)
Week 14-64.15 (-78.24 to -50.05)-47.87 (-62.17 to -33.56)-63.20 (-74.36 to -52.05)-44.30 (-57.51 to -31.09)-83.39 (-89.74 to -77.04)-47.84 (-60.18 to -35.49)-47.52 (-59.86 to -35.18)-39.48 (-52.09 to -26.88)
Week 16-57.28 (-72.02 to -42.54)-38.48 (-51.85 to -25.10)-60.56 (-72.71 to -48.42)-36.63 (-51.43 to -21.83)-74.18 (-83.22 to -65.15)-44.58 (-58.96 to -30.19)-42.29 (-59.96 to -24.63)-38.79 (-51.92 to -25.66)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Time frame:
From first dose of study treatment (Day 1) up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Treatment-emergent AEs1921181821162313
Treatment-emergent SAEs21110000
SecondaryNumber of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs

The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).

Time frame:
From first dose of study treatment (Day 1) up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs
ParticipantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs24120220
SecondaryChange From Baseline in Blood Lipid Level at Weeks 4 and 12

Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.

Time frame:
Baseline (Day 1 pre-dose), Weeks 4 and 12
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Blood Lipid Level at Weeks 4 and 12
milligram per deciliter (mg/dL)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
LDL Cholesterol, Week 415.91 (7.95 to 23.86)11.27 (4.31 to 18.23)15.00 (-0.63 to 30.63)15.88 (6.63 to 25.12)8.96 (0.99 to 16.92)-2.21 (-11.04 to 6.63)7.60 (-4.39 to 19.59)-6.28 (-10.56 to -2.00)
LDL Cholesterol, Week 128.71 (1.04 to 16.39)6.00 (-4.73 to 16.73)-0.74 (-11.67 to 10.20)6.85 (-2.06 to 15.76)14.10 (6.63 to 21.57)-5.33 (-18.24 to 7.57)3.95 (-7.79 to 15.70)-4.00 (-9.71 to 1.71)
HDL Cholesterol, Week 412.09 (8.07 to 16.11)9.14 (5.84 to 12.45)10.92 (7.38 to 14.46)8.58 (5.84 to 11.33)6.36 (3.91 to 8.80)6.76 (2.93 to 10.59)9.39 (7.03 to 11.75)0.00 (-5.14 to 5.14)
HDL Cholesterol, Week 125.00 (1.29 to 8.71)5.48 (1.66 to 9.29)2.48 (-0.31 to 5.26)-0.24 (-2.55 to 2.08)4.74 (1.30 to 8.18)4.37 (1.04 to 7.70)2.88 (-0.24 to 5.99)-2.73 (-6.32 to 0.85)
Total Cholesterol, Week 434.39 (24.01 to 44.77)29.46 (18.68 to 40.25)31.32 (15.20 to 47.44)26.33 (15.85 to 36.82)15.14 (-0.16 to 30.45)10.36 (-1.70 to 22.42)14.00 (0.14 to 27.86)-4.42 (-10.90 to 2.06)
Total Cholesterol, Week 1219.50 (9.95 to 29.05)15.67 (2.74 to 28.59)-1.86 (-13.78 to 10.07)7.05 (-3.25 to 17.35)20.37 (3.06 to 37.68)0.68 (-14.51 to 15.87)4.33 (-8.86 to 17.53)-6.40 (-13.68 to 0.88)
Triglycerides, Week 434.74 (-8.43 to 77.91)29.68 (10.42 to 48.94)8.04 (-20.07 to 36.15)8.92 (-21.83 to 39.66)-65.11 (-204.94 to 74.72)19.60 (-3.04 to 42.24)-59.75 (-157.79 to 38.29)15.26 (-11.07 to 41.60)
Triglycerides, Week 1227.86 (-4.68 to 60.41)48.33 (-32.67 to 129.34)-85.00 (-213.81 to 43.81)2.67 (-27.36 to 32.70)-18.96 (-198.51 to 160.59)6.32 (-19.21 to 31.84)-67.79 (-185.53 to 49.95)1.87 (-24.28 to 28.01)
SecondaryNumber of Participants With Any Post-Baseline Laboratory Test Abnormalities

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).

Time frame:
From first dose of study treatment (Day 1) up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Any Post-Baseline Laboratory Test Abnormalities
ParticipantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Number of Participants With Any Post-Baseline Laboratory Test Abnormalities1720201621201811
SecondaryNumber of Participants With Post-Baseline Vital Sign Abnormalities

Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.

Time frame:
From first dose of study treatment (Day 1) up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Vital Sign Abnormalities
ParticipantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Sitting DBP <50 mm Hg00000000
Sitting DBP increase >=20 mm Hg11320000
Sitting DBP decrease >=20 mm Hg30221221
Sitting SBP <90 mm Hg11000000
Sitting SBP increase >=30 mm Hg13210100
Sitting SBP decrease >=30 mm Hg22121321
Sitting pulse rate <40 bpm00000000
Sitting pulse rate >120 bpm00000100
SecondaryNumber of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.

Time frame:
From first dose of study treatment (Day 1) up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
ParticipantsPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
PR interval >=300 msec00101000
%Change in PR interval >=25/50%00000100
QRS duration >=140 msec01000000
%Change in QRS duration >=50%00000010
QT interval >=500 msec00000000
QTc >=450 to <480 msec61201101
QTc >=480 to <500 msec00100001
QTc >=500 msec00000000
QTc change >=30 to <60 msec20213301
QTc change >=60 msec00200001

Adverse events

Collected over From first dose of study treatment up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD1/25 (4%)2/25 (8%)11/25 (44%)
PF-06700841 60 mg QD Followed by 10 mg QD0/29 (0%)1/29 (3.4%)14/29 (48.3%)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)0/26 (0%)1/26 (3.8%)13/26 (50%)
PF-06700841 60 mg QD Followed by Placebo0/25 (0%)1/25 (4%)13/25 (52%)
PF-06700841 30 mg QD0/29 (0%)0/29 (0%)13/29 (44.8%)
PF-06700841 30 mg QD Followed by 10 mg QD0/25 (0%)0/25 (0%)12/25 (48%)
PF-06700841 30 mg QD Followed by 100 mg QW0/30 (0%)0/30 (0%)16/30 (53.3%)
Placebo0/23 (0%)0/23 (0%)9/23 (39.1%)
Most frequent serious events
Most frequent serious events
EventPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
Angina pectorisCardiac disorders1/250/290/260/250/290/250/300/23
Chest painGeneral disorders0/250/290/261/250/290/250/300/23
Gun shot woundInjury, poisoning and procedural complications1/250/290/260/250/290/250/300/23
PneumoniaInfections and infestations0/250/291/260/250/290/250/300/23
SepsisInfections and infestations0/250/291/260/250/290/250/300/23
AnaemiaBlood and lymphatic system disorders0/251/290/260/250/290/250/300/23
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlacebo
NasopharyngitisInfections and infestations4/253/293/263/255/296/254/303/23
Upper respiratory tract infectionInfections and infestations2/251/295/261/252/290/253/301/23
HeadacheNervous system disorders1/252/293/263/254/291/250/301/23
PruritusSkin and subcutaneous tissue disorders0/250/291/263/251/290/251/300/23
PsoriasisSkin and subcutaneous tissue disorders0/251/293/261/250/292/250/300/23
DiarrhoeaGastrointestinal disorders0/251/290/261/250/291/253/301/23
NauseaGastrointestinal disorders1/251/291/262/250/290/251/302/23
Back painMusculoskeletal and connective tissue disorders1/252/290/260/252/292/251/302/23
FatigueGeneral disorders1/251/291/262/250/291/250/301/23
VomitingGastrointestinal disorders0/251/291/261/250/292/250/300/23

Baseline characteristics

All participants who received at least 1 dose of PF-06700841 or placebo.

Age, Continuous
Age, Continuous(years)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlaceboTotal
Mean49.0 ± 14.6944.6 ± 13.7145.5 ± 12.9348.4 ± 15.4744.2 ± 10.9244.0 ± 11.5643.2 ± 12.2850.3 ± 12.2346.0 ± 13.04
Age, Customized
Age, Customized(Participants)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlaceboTotal
18-44 Years814108141214888
45-64 Years1413141314131612109
>=65 Years3224100315
Sex: Female, Male
Sex: Female, Male(Participants)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlaceboTotal
Female981441087464
Male1621122119172319148
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlaceboTotal
Hispanic or Latino4442654433
Not Hispanic or Latino2125222323202619179
Unknown or Not Reported000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QDPF-06700841 60 mg QD Followed by 10 mg QDPF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)PF-06700841 60 mg QD Followed by PlaceboPF-06700841 30 mg QDPF-06700841 30 mg QD Followed by 10 mg QDPF-06700841 30 mg QD Followed by 100 mg QWPlaceboTotal
White2227232427222519189
Black or African American3030111211
Asian010100204
American Indian or Alaska Native010001013
Native Hawaiian or Other Pacific Islander000001102
Other000010113
08

Study locations

44 sites
  • Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA
    Rogers, Arkansas 72758, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Emil A. Tanghetti, MD dba Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Tower Saint John's Imaging
    Santa Monica, California 90403, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Park Avenue Dermatology Administrative Annex
    Orange Park, Florida 32073, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Rose Radiology
    Tampa, Florida 33609, United States
  • Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dawes Fretzin Dermatology Group, LLC
    Indianapolis, Indiana 46256, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • The Rockefeller University
    New York, New York 10065, United States
  • Skin Search of Rochester, Inc.
    Rochester, New York 14623, United States
  • Investigational Drug Services, UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • UNC Dermatology and Skin Cancer Center
    Chapel Hill, North Carolina 27516, United States
  • UNC Clinical and Translation Research Center
    Chapel Hill, North Carolina 27599, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Vital Prospects Clinical Research Institute, P.C
    Tulsa, Oklahoma 74136, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Lee Medical Associates, PA
    San Antonio, Texas 78213, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • Research by ICLS
    Oakville, Ontario L6J 7W5, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • K.Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Quebec, G1V4X7, Canada
  • Centrum Medyczne Enel-Med Przychodnia Grunwaldzka
    Gdansk, 80-266, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdansk, 80-546, Poland
  • Dermoklinika Centrum Medyczne s.c. M.Kierstan, J. Narbutt, A. Lesiak
    Lodz, 90-436, Poland
  • NZOZ "Nasz Lekarz" - Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna
    Torun, 87-100, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warszawa, 02-106, Poland
  • WroMedica s.c.
    Wroclaw, 51-685, Poland
09

References and documents

Publications

  • Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1447-1456. doi: 10.1002/cpdd.1163. Epub 2022 Aug 31. PubMed 36045513 ↗
  • Forman SB, Pariser DM, Poulin Y, Vincent MS, Gilbert SA, Kieras EM, Qiu R, Yu D, Papacharalambous J, Tehlirian C, Peeva E. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. J Invest Dermatol. 2020 Dec;140(12):2359-2370.e5. doi: 10.1016/j.jid.2020.03.962. Epub 2020 Apr 18. PubMed 32311398 ↗
  • Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16. PubMed 30113844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2018, 15 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 15 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 21, 2016
StartActual
Dec 2016
Primary completionActual
Mar 2018
CompletionActual
Mar 2018
Results first posted
Mar 29, 2019
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02969018
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Dec 2016
Primary completion
Mar 2018
Completion
Mar 2018
Results posted
Mar 29, 2019
Last update
Mar 29, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion